en English
af Afrikaanssq Shqipam አማርኛar العربيةhy Հայերենaz Azərbaycan dilieu Euskarabe Беларуская моваbn বাংলাbs Bosanskibg Българскиca Catalàceb Cebuanony Chichewazh-CN 简体中文zh-TW 繁體中文co Corsuhr Hrvatskics Čeština‎da Dansknl Nederlandsen Englisheo Esperantoet Eestitl Filipinofi Suomifr Françaisfy Fryskgl Galegoka ქართულიde Deutschel Ελληνικάgu ગુજરાતીht Kreyol ayisyenha Harshen Hausahaw Ōlelo Hawaiʻiiw עִבְרִיתhi हिन्दीhmn Hmonghu Magyaris Íslenskaig Igboid Bahasa Indonesiaga Gaeligeit Italianoja 日本語jw Basa Jawakn ಕನ್ನಡkk Қазақ тіліkm ភាសាខ្មែរko 한국어ku كوردی‎ky Кыргызчаlo ພາສາລາວla Latinlv Latviešu valodalt Lietuvių kalbalb Lëtzebuergeschmk Македонски јазикmg Malagasyms Bahasa Melayuml മലയാളംmt Maltesemi Te Reo Māorimr मराठीmn Монголmy ဗမာစာne नेपालीno Norsk bokmålps پښتوfa فارسیpl Polskipt Portuguêspa ਪੰਜਾਬੀro Românăru Русскийsm Samoangd Gàidhligsr Српски језикst Sesothosn Shonasd سنڌيsi සිංහලsk Slovenčinasl Slovenščinaso Afsoomaalies Españolsu Basa Sundasw Kiswahilisv Svenskatg Тоҷикӣta தமிழ்te తెలుగుth ไทยtr Türkçeuk Українськаur اردوuz O‘zbekchavi Tiếng Việtcy Cymraegxh isiXhosayi יידישyo Yorùbázu Zulu

Kidney Tumors

Kidney cancer is a disease that starts in the kidneys. It happens when healthy cells in one or both kidneys grow out of control and form a lump (called a tumor).

Renal cell carcinoma is the most common type of kidney cancer in adults. It most often begins in the lining of tiny tubes in the kidney (called “renal tubules”). The renal tubules clean your blood and make urine. Renal cell cancer often stays within the kidney, but it may spread to other parts of the body, most often the bones, lungs, or brain. There are many different types of renal cell carcinoma and about 9 out of 10 kidney cancers are renal cell carcinomas.


Kidney Subtypes:

Clear cell renal cell carcinoma – this is the most common form of renal cell carcinoma. About 7 out of 10 people with RCC have this kind of cancer. When seen under a microscope, the cells that make up clear cell RCC look very pale or clear.
Papillary renal cell carcinoma – this is the second most common subtype – about 1 in 10 RCCs are of this type. These cancers form little finger-like projections (called papillae) in some, if not most, of the tumor. Some doctors call these cancers chromophilic because the cells take in certain dyes and look pink under the microscope.
Chromophobe renal cell carcinoma – this subtype accounts for about 5% (5 cases in 100) of RCCs. The cells of these cancers are also pale, like the clear cells, but are much larger and have certain other features that can be recognized when looked at with a microscope .
Rare types of renal cell carcinoma – these subtypes are very rare, each making up less than 1% of RCCs:
Unclassified renal cell carcinoma – rarely, renal cell cancers are labeled as unclassified because the way they look doesn’t fit into any of the other categories or because there is more than one type of cell present.

Risk Factors:

According to the American Cancer Society, about half of kidney cancers could potentially be prevented with the elimination of excess body weight and tobacco smoking, which are the strong risk factors. Additional risk factors include:
– High Blood Pressure
– Chronic Renal Failure
– occupational Exposure to Certain Chemicals
– Radiation Exposure
– Rare Hereditary Conditions


How Our Team Treats Kidney Cancer

Due to the kidney’s location in the body, near the bowel and lungs, there is constant movement from regular bodily functions. Most other radiation therapy solutions require the patient to wear uncomfortable braces and devices to help stabilize the body as much as possible during treatment. Even still, there is the possibility that the tumor does not receive as much of the radiation as it should, which can pose a risk to surrounding organs and tissues.

CyberKnife challenges conventional radiation therapy with its advanced technology and robotic design. With enhanced image guidance and tumor-tracking software, CyberKnife can target the exact location of the tumor and adjust to its movements during treatment. CyberKnife’s ability to track the tumor minimizes radiation exposure to other organs, tissues, and nerves, and it ensures that the tumor receives high doses of radiation with sub-millimeter accuracy. The patient is also more comfortable during treatment with CyberKnife since no stabilization hardware is required.

CyberKnife’s Advantage

  • It’s nonsurgical, meaning no incisions
  • There is no anesthesia or hospitalization required
  • It’s painless
  • It’s completed in five or fewer outpatient treatment sessions
  • There is little to no recovery time, allowing for an immediate return to daily activities
  • There are minimal, if any, side effects
  • Due to pinpoint precision of high-dose radiation delivery, there is minimal radiation exposure to healthy tissue surrounding a tumor
  • CyberKnife can treat patients that have previously had surgery, gone through radiation therapy, or are currently undergoing radiation therapy for liver cancer

Speak with one of our dedicated Team Members about how we can help today.